alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The market jumped so much this morning that even ENTA is up. Will wonders never cease!
Well, that was fun! 😩
I never assume I can call the bottom for any stock. I bought half the amount of my usual buy when I bought a bit more of RVNC. today. I am also factoring in that I need a tax loss if the PFE buyout of SGEN completes in this calendar year, which is looking less likely now. If it does complete in 2023 then I need to be able to book a tax loss so my time to be a buyer of RVNC is closing. Sadly, both RVNC and ENTA are giving me plenty of tax loss selling opportunities.
Sounds like providers are quite pleased with Daxxify.
Thanks. As I surmised, Botox and the 20u dose of their own drug was about 5 month’s duration using their non-standard metric, almost as good as their 6 month claim for their 40u dosage. We know Botox lasts only ~3 months so their lying/using their non-standard metric is presenting a false picture of true duration. If they were honest they would admit they cannot compare Daxxify to their 40u doses because different metrics were used. RVNC used the standard required by the FDA. EOLS did not.
That must be the undisclosed virology candidate listed on the ENTA web site.
They were wrong on their initial price target and are now wrong about the new pricing strategy. Their criticism of the new pricing strategy could be their attempt to provide a rationale for dropping their price target without admitting they were too optimistic too soon..
IMGN earnings call. Very positive outlook.
https://www.insidermonkey.com/blog/immunogen-inc-nasdaqimgn-q3-2023-earnings-call-transcript-1216225/?singlepage=1
IMGN earnings call. Very positive outlook.
https://www.insidermonkey.com/blog/immunogen-inc-nasdaqimgn-q3-2023-earnings-call-transcript-1216225/?singlepage=1
My revenue estimates would be meaningless. The revenue estimates for Q3 don’t really matter in the long run. Since you want an estimate, my guess is $26.39 million to $26.52 million for Daxxify in Q3. Is that specific enough for you?
You claim to have good insights based on products launched 5 years ago, 10 years ago or longer. I will be interesting to see how that bears out for Q3, Q4 and beyond.
Good news for IMGN shareholders today as Elahere sales for Q3 beat expectations and came in at $105 million and net income of $30 million or $0.10 per share for $210 million in sales for the first 9 month of this year. IMGN has just over $600 million in cash and cash equivalents on hand now.
IMGN also reported that Elahere met the primary end point of ORR in PSOC in the PICCOLO trial, an open label phase 2 trial. Full data is expected by mid 2024 but an ORR of at least 48% is expected. The PSOC market is twice as large as PROC, which is the indication that IMGN has submitted for full approval in both the US and Europe based on the stellar MIRASOL phase 3 trial data.
https://finance.yahoo.com/news/immunogen-reports-recent-progress-third-103000189.html
Blowout earnings report propelling a nice rise in the stock price today. Congrats to all us IMGN shareholders!!
Sab,
That sounds really tough. Sorry you ended up suffering like that.